Gene Signature Sets Predict Recurrence, Chemotherapy Benefit in Stage 2 Colorectal Cancer

Share this content:
Hallmark-base gene signature sets are more accurate and robust predictors of prognosis and identification in stage 2 colorectal cancer.
Hallmark-base gene signature sets are more accurate and robust predictors of prognosis and identification in stage 2 colorectal cancer.

Hallmark-base gene signature sets (CSS sets) are more accurate and robust predictors of prognosis and identification of patients with stage 2 colorectal cancer (CRC) who would benefit from fluoropyrimidine-based adjuvant therapy, according to an article published online ahead of print in JAMA Oncology.1

The topic of adjuvant therapy for patients with stage 2 CRC has been a controversial issue throughout the past 2 decades. Researchers sought to develop combinatory cancer hallmark-based CSS sets that could accurately predict prognosis and identify a subset of patients who would benefit from adjuvant chemotherapy.

Researchers analyzed 13 retrospective studies, which included 1,005 patients with stage 2 CRC who had clinical follow-up and adjuvant chemotherapy. Three independent cohorts had patients treated with fluorouracil-based adjuvant therapy.

Researchers identified 8 cancer hallmark-based gene signatures (30 genes each) to construct CSS sets for determination of prognosis.

RELATED: Colorectal Low-, High-Mucinous Carcinomas Should Be Differentiated in Clinical Settings

The sets were validated in 11 cohorts of 767 patients who did not receive adjuvant chemotherapy. Results showed that CSS sets accurately grouped patients into low- (60% of patients), intermediate- (28%), and high-risk (12%) groups.

Five-year relapse survival rates were 94%, 78%, and 45%, respectively. The patients who received fluorouracil-based adjuvant chemotherapy had a survival benefit: recurrence rates were reduced by 30% to 40% in 5 years.

Reference

  1. Gao S, Tibiche C, Zou J, et al. Identification and construction of combinatory cancer hallmark-based gene signature sets to predict recurrence and chemotherapy benefit in stage II colorectal cancer [published online ahead of print October 22, 2015]. JAMA Oncol. doi: 10.1001/jamaoncol.2015.3413.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs